NCT05634447View on ClinicalTrials.gov

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

February 27, 2023

Study Completion Date

June 7, 2023

Conditions
Dyslipidemias
Interventions
DRUG

Drug: CKD-391, QD, PO

Drug: CKD-331, D337 QD, PO

Trial Locations (1)

07590

Bumin Hospital(Seoul), Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05634447 - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391 | Biotech Hunter | Biotech Hunter